Terapie
komórkami macierzystymi

Terapie komórkami macierzystymi

Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).

Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.

Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.

Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.

Data aktualizacji: 06.2026

Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord

Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
Lp.	Źródło	Typ źródła	Wskazanie	Obszar medycyny	Rok podania	Terapia	Kraj	Wiek odbiorcy
101	Bone Marrow Family	Allogeneic	Acute Myeloid Leukemia (Relapse)	Hematology	2026	Standard Therapy	Germany	66
102	Bone Marrow Family	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Germany	70
103	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	France	42
104	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Netherlands	57
105	Bone Marrow Family	Allogeneic	Polycythaemia Vera	Hematology	2026	Standard Therapy	Germany	61
106	Bone Marrow Family	Allogeneic	CMML – Beginning Relapse	Hematology	2026	Standard Therapy	Netherlands	63
107	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Australia	64
108	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	76
109	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Switzerland	66
110	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Finland	40
111	Bone Marrow Family	Allogeneic	T-Cell Prolymphocytic Leukemia	Hematology	2026	Standard Therapy	Norway	64
112	Bone Marrow Family	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	Spain	47
113	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	66
114	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Czechia	68
115	Bone Marrow Family	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Poland	26
116	Bone Marrow Family	Allogeneic	Acute Myeloid Leukemia	hematology	2026	Standard Therapy	Germany	67
117	Bone Marrow Family	Allogeneic	Acute Myeloid Leukemia	hematology	2026	Standard Therapy	Germany	51
118	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	hematology	2026	Standard Therapy	France	67
119	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	hematology	2026	Standard Therapy	USA	30
120	Bone Marrow Family	Allogeneic	Acute Lymphoblastic Leukemia	hematology	2026	Standard Therapy	Hungary	10
121	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	hematology	2026	Standard Therapy	Germany	63
122	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia / MDR Relapse	hematology	2026	Standard Therapy	Ukraine	39
123	Bone Marrow Family	Allogeneic	Chronic Myelomonocytic Leukemia	hematology	2026	Standard Therapy	USA	70
124	Bone Marrow Family	Allogeneic	Acute Myelogenous Leukemia	hematology	2026	Standard Therapy	Poland	72
125	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Germany	3
126	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Hungary	62
127	Bone Marrow	Allogeneic	Fanconi Anemia	Hematology	2026	Standard Therapy	Austria	7
128	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Belgium	12
129	Bone Marrow	Allogeneic	Combined Immunodeficiency	Hematology	2026	Standard Therapy	Belgia	3
130	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Italy	60
131	Bone Marrow	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	Italy	7
132	Bone Marrow	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	Italy	4
133	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Germany	8
134	Bone Marrow	Allogeneic	Other Immune System	Hematology	2026	Standard Therapy	USA	5
135	Bone Marrow	Allogeneic	Adrenoleukodystrophy (X-ALD)	Hematology	2026	Standard Therapy	Czechia	5
136	Bone Marrow	Allogeneic	Wiskott-Aldrich Syndrome	Hematology	2026	Standard Therapy	Germany	19
137	Bone Marrow	Allogeneic	Wiskott-Aldrich Syndrome	Hematology	2026	Standard Therapy	USA	11
138	Bone Marrow	Allogeneic	Serum Amyloid A (SAA)	Hematology	2026	Standard Therapy	Austria	16
139	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	France	32
140	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	Germany	16
141	Bone Marrow	Allogeneic	Other Malignancy	Hematology	2026	Standard Therapy	France	5
142	Bone Marrow	Allogeneic	Mixed type Leukemia	Hematology	2026	Standard Therapy	Poland	1
143	Bone Marrow	Allogeneic	OIID, Chronic Granulomatous Disease CGD	Hematology	2026	Standard Therapy	Germany	2
144	Bone Marrow	Allogeneic	GATA2 deficiency	Hematology	2026	Standard Therapy	Belgium	12
145	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Italy	48
146	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	47
147	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	United Kingdom	80
148	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	United Kingdom	15
149	Bone Marrow	Allogeneic	Severe Aplastic Anemia / AA Amyloidosis	Hematology	2026	Standard Therapy	United Kingdom	24
150	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Turkey	8
151	Bone Marrow	Allogeneic	SCID Severe Combined Immunodeficiency	Hematology	2026	Standard Therapy	Poland	1
152	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	Germany	58
153	Bone Marrow	Allogeneic	Pure Red Cell Aplasia	Hematology	2026	Standard Therapy	USA	29
154	Bone Marrow	Allogeneic	Combined Immunodeficiency	Hematology	2026	Standard Therapy	USA	19
155	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	France	21
156	Bone Marrow	Allogeneic	B-thalassemia	Hematology	2026	Standard Therapy	Netherlands	15
157	Bone Marrow	Allogeneic	Very Severe Aplastic Anemia	Hematology	2026	Standard Therapy	Slovakia	31
158	Bone Marrow	Allogeneic	Hemophagocytic Lymphohistiocytosis	Hematology	2026	Standard Therapy	Austria	3
159	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	12
160	Bone Marrow	Allogeneic	Diamond Blackfan Anemia	Hematology	2026	Standard Therapy	Slovakia	9
161	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Brazil	62
162	Bone Marrow	Allogeneic	Griscelli syndrome type 2	Hematology	2026	Standard Therapy	Canada	39
163	Bone Marrow	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	France	47
164	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	USA	21
165	Bone Marrow	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	Hungary	10
166	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	70
167	Bone Marrow	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	USA	6
168	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia CR2	Hematology	2026	Standard Therapy	Spain	9
169	Bone Marrow	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	France	7
170	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Hungary	23
171	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	USA	8
172	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	USA	20
173	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	1
174	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	USA	13
175	Bone Marrow	Allogeneic	Severe Combined Immunodeficiency	Hematology	2026	Standard Therapy	USA	2
176	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	Italy	3
177	Bone Marrow	Allogeneic	Non-Hodgkin Lymphoma	Hematology	2026	Standard Therapy	USA	26
178	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Hungary	9
179	Bone Marrow	Allogeneic	Chronic Myelomonocytic Leukemia	Hematology	2026	Standard Therapy	Spain	61
180	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Germany	2
181	Bone Marrow	Allogeneic	Other Leukaemia	Hematology	2026	Standard Therapy	France	1
182	Bone Marrow	Allogeneic	–	Hematology	2026	Standard Therapy	Germany	16
183	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	Belarus	2
184	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	United Kingdom	11
185	Bone Marrow	Allogeneic	Sickle Cell Disease	hematology	2026	Standard Therapy	Netherlands	18
186	Bone Marrow	Allogeneic	Non-Hodgkin Lymphoma	hematology	2026	Standard Therapy	Germany	6
187	Bone Marrow	Allogeneic	Fanconi Anemia	hematology	2026	Standard Therapy	USA	7
188	Bone Marrow	Allogeneic	Other Combined Immunodeficiency	hematology	2026	Standard Therapy	USA	8
189	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	hematology	2026	Standard Therapy	Spain	14
190	Bone Marrow	Allogeneic	Acute Lymphoblastic Leukemia	hematology	2026	Standard Therapy	Poland	3
191	Bone Marrow	Allogeneic	Myelodysplastic Syndrome	hematology	2026	Standard Therapy	Italy	1
192	Bone Marrow	Allogeneic	Severe Aplastic Anemia	hematology	2026	Standard Therapy	USA	76
193	Bone Marrow	Allogeneic	Acute Myelogenous Leukemia	hematology	2026	Standard Therapy	Germany	38
194	Bone Marrow	Allogeneic	Sickle cell disease	hematology	2026	Standard Therapy	Netherlands	17
195	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	61
196	Apheresis	Autologous	Plasmablastic Lymphoma	Hematology	2026	Standard Therapy	Germany	69
197	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	60
198	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Portugal	54
199	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Portugal	67
200	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	France	68

Poprzednia

Strona 2 z 89 1 2 3 4 89

Następna